Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZBTB20 antisense RNA 4 (ZBTB20-AS4) is a long non-coding RNA transcribed in antisense orientation to the ZBTB20 gene. While ZBTB20 itself encodes a transcription factor involved in differentiation, immunity, and liver development[1][2][4], ZBTB20-AS4 does not encode any protein and has no experimentally validated molecular function, disease relevance, or therapeutic targeting information reported to date. Its annotation as a non-protein coding antisense transcript is current, but its biological significance remains undefined[3]. ZBTB20-AS4 is distinct from the protein-coding gene ZBTB20, which has recognized roles such as transcriptional repression in immune and developmental pathways[1][2][4]. ZBTB20-AS4’s lack of functional characterization means it is not considered a canonical therapeutic target, biomarker, or drug-interaction partner at present. This assessment is based on current molecule and gene catalog listings, as well as absence of functional or disease-related data in major molecular biology references[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZBTB20 antisense RNA 4 (ZBTB20-AS4).